Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    An NIH-wide banner about terminology changes during a transition appeared, and the site revision advanced from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:26:10.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T20:54:05.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content. The surrounding header and navigation remain visible, but the main study information is not accessible.
    Difference
    18%
    Check dated 2026-09-22T22:52:41.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page revision has been updated from v3.6.6 to v3.7.0 on the Study Details page. This reflects a page-level update (likely maintenance or UI/content management change) rather than modifications to the study data, eligibility criteria, or results.
    Difference
    0.0%
    Check dated 2026-09-15T20:31:14.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6, indicating a new page revision. This change does not alter the study details or content presented to users.
    Difference
    0.0%
    Check dated 2026-09-01T18:15:54.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page gained new metadata entries: 2014 ( U.S. NIH Grant/Contract ), Melanoma, related topics:, and MedlinePlus Genetics. These additions expand funding context and link to related resources.
    Difference
    0.1%
    Check dated 2026-08-25T20:47:30.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.